**Event Adjudication**

**end-to-end traceability**

**Introduction**

Event adjudication is a review done by two independent medical specialists who assesses events for fulfillment of pre-defined clinical criteria.

Adjudication data do not replace or otherwise modify investigator reported data.

In Novo Nordisk adjudication data is used to assess key efficacy and safety variables in primary and secondary analyses, in addition to the investigator reported data.

The poster presents Novo Nordisk’s approach to a data standard for adjudication data, and how it supports end-to-end traceability.

**Requirements**

- **Technical Conformance Guide:** ‘Whenever adjudication data is provided it should be clearly identified so that the reviewer can distinguish the results of adjudication from data as originally collected’.

- Assessments from different types of events in different clinical settings are to be captured and reported.

**SDTM considerations**

- Novo Nordisk has implemented a sponsor defined stand-alone domain with the Findings About concept.

- Only the final agreed assessments from the two independent adjudicators are submitted in our SDTM data set.

**Standardised data collection design**

**Conclusions**

Currently the SDTMIG does not offer explicit guidance on how adjudication results are to be represented in SDTM. We would all benefit from standardised data collection and more guidance in SDTm standards within this area.

**March 2018**